Recruiting
Phase 1

Efimosfermin Alfa

Sponsor:

GlaxoSmithKline

Code:

NCT07358546

Conditions

Non-alcoholic Fatty Liver Disease

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Efimosfermin alfa

Study Details

Brief summary:

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

Conditions

Non-alcoholic Fatty Liver Disease

Study ID

NCT07358546

Start date

Mar 13, 2026

Status verified date

May, 2026

Completion date

Oct 13, 2027

Anticipated

Primary completion date

Oct 13, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Between 18 years and 70 years of age inclusive
  • Body Mass Index (BMI) within the range 23-40 kilogram per square meter (kg/m\^2)
  • Male or female participants
  • Participant has liver cirrhosis with a grade of hepatic impairment that can be classified as a discrete Child-Pugh class. Participants must:

  • Have a clinical diagnosis of liver cirrhosis in the participant's medical history corroborated by previous liver biopsy, medical imaging or compatible biochemical profile, and
  • Be classed during Screening as one of the following Child-Pugh classes:

  • Child-Pugh B: Score 7-9 or
  • Child-Pugh C: Score 10-15
  • Chronic (greater than \[>\] 6 months) HI which is currently stable (no acute episodes of illness within the previous 1 month prior to Screening (Visit 1) due to deterioration in hepatic function). Participants must also remain stable throughout the Screening period. Assessment of the stability of the participant's hepatic function will be determined by the investigator.

Exclusion Criteria:

  • History of extrahepatic disorders possibly related to etiology of cirrhosis.
  • History of cryoglobulinemia.
  • Participants with Grade 3 ascites or refractory ascites.
  • Participants with refractory encephalopathy or significant central nervous system disease
  • History of gastric or esophageal variceal bleeding within the past 6 months and for which varices have not been adequately treated with medication and/or surgical procedures.
  • Other primary causes of liver disease. Steatotic liver disease must be the primary cause of liver disease.
  • Clinically significant abnormalities affecting physical health in medical history, or on physical examination, that could interfere with or for which treatment could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study.
  • Current, or history of known hepatocellular carcinoma (HCC).
  • Participants with transjugular intrahepatic portosystemic shunt (TIPS) placement.
  • Presence of hepatopulmonary or hepatorenal syndrome.
  • Presence of primarily cholestatic liver diseases.
  • Evidence of symptomatic or complicated cholecystitis.
  • History of pancreatic injury, pancreatitis, or other pancreatic disease.
  • History of liver transplantation, or active on the liver transplant waiting list.
  • Participants with signs of active infection
  • History of adrenal gland disease or using treatment that affects the hypothalamic-pituitary-adrenal axis.
  • History of significant bone disease such as osteoporosis
  • Psychosocial features that, in the opinion of the investigator, increase the likelihood of loss to follow-up.
  • History or presence of drug abuse.
  • Use of other investigational drugs at the time of screening, or within 5 half-lives or 30 days prior to study intervention, whichever was longer; or longer if required by local regulations
  • Have previously taken efimosfermin alfa
  • Participants with Alanine Aminotransferase (ALT) value >3 times (x) upper limit of normal (ULN)
  • Participants with Aspartate aminotransferase (AST) value >=300 Units/Liter.
  • Participants with estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology \[CKD-Epi\] 2021) <45 milliliter/minute/1.73 square meter (mL/min/1.73m\^2).
  • Average of triplicate QT interval corrected for heart rate using Fridericia formula (QTcF) >480 milliseconds (msec) (for male and female participants) at Screening
  • For participants in the MASH with alcohol category, significant risk of withdrawal symptoms.

Study Design

Enrollment

32 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Efimosfermin alfa in participants with moderate hepatic impairment due to MASH without alcohol

All participants will receive efimosfermin alfa. Participants will have moderate hepatic impairment (Child-Pugh B) due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) with typical alcohol consumption threshold in the 3 months prior to Screening of less than (<) 5 standard drinks on any day and <15 standard drinks per week for men; or <4 standard drinks on any day and <8 standard drinks per week for women.

experimental: Efimosfermin alfa in participants with moderate hepatic impairment due to MASH with alcohol

All participants will receive efimosfermin alfa. Participants will have moderate hepatic impairment (Child-Pugh B) due to MASH with typical alcohol consumption threshold in the 3 months prior to Screening of greater than or equal to (>=) 5 standard drinks per day or >=15 standard drinks per week for men; or >= 4 standard drinks per day or >=8 or more drinks per week for women.

experimental: Efimosfermin alfa in severe hepatic impairment participants due to MASH regardless of alcohol use

All participants will receive efimosfermin alfa. Participants will have severe hepatic impairment (Child-Pugh C) due to MASH with any typical daily alcohol consumption.

Interventions

Efimosfermin alfa

Efimosfermin alfa to be administrated subcutaneously

Primary outcome measure

  • Area under the serum drug concentration versus time curve from time zero to infinity (AUC[0-inf]) of efimosfermin alfa [ Time Frame: Up to 90 Days ]
  • Maximum observed serum drug concentration (Cmax) of efimosfermin alfa [ Time Frame: Up to 90 Days ]

Central Contacts and Locations

Central contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

+44 (0) 20 89904466GSKClinicalSupportHD@gsk.com

Locations

GSK Investigational Site

Recruiting

Rialto, California, United States, 92377

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Zeid Kayali

GSK Investigational Site

Recruiting

Tampa, Florida, United States, 33603

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Jesus Navarro

GSK Investigational Site

Recruiting

San Antonio, Texas, United States, 78215

Contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Centre

+44 (0) 20 8990 4466GSKClinicalSupportHD@gsk.com

Principal Investigator:

Eric Lawitz

More Information

Sponsor

GlaxoSmithKline

Last update posted

Jun 9, 2026

Last verified

May, 2026

Keywords

  • efimosfermin alfa
  • Alcohol
  • Hepatic Impairment
  • Steatotic liver disease
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Pharmacokinetics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-06-09.